



Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases


SUPPLEMENTARY MATERIALS





Supplementary Figure S1: qPCR of Egfr-family members in MCF-7 after 72h treatment with 10μM tamoxifen, 0.5μM salinomycin or the combination thereof.



Supplementary Figure S2: Time projection of HeLa cells treated with 6μM of salinomycin and analyzed by spinning disc microscopy.



Supplementary Figure S3: IC_{50} of salinomycin in MCF-7 TAM-R6. Tamoxifen resistant cells were treated with indicated concentrations of salinomycin for 72h and afterwards analyzed by Cell Titer Glo[®] Assay.



Supplementary Figure S4: IC_{50} of tamoxifen and salinomycin in T47D. T47D were treated with indicated concentrations of tamoxifen or salinomycin for 72h and analyzed by Cell Titer Glo® Assay.